ストックスクリーナーアプリを入手
6.05
5.02%
-0.32
アフターアワーズ：
6.05
前日終値:
$6.37
開ける：
$6.33
24時間の取引高:
276.25K
Relative Volume:
1.06
時価総額：
$359.76M
収益：
$2.91M
当期純損益:
$-220.40M
株価収益率:
-1.148
EPS:
-5.27
ネットキャッシュフロー:
$-176.15M
1週間 パフォーマンス:
-7.07%
1か月 パフォーマンス:
-39.74%
6か月 パフォーマンス:
-11.94%
1年 パフォーマンス:
-27.20%
1日の値動き範囲:
$5.91
$6.455
1週間の範囲:
$5.91
$6.77
52週間の値動き範囲:
$5.91
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
名前
Igm Biosciences Inc
セクター
電話
650-965-7873
住所
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
IGMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
6.05 | 359.76M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-10-01 | ダウングレード | Truist | Buy → Hold |
| 2024-02-09 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-11-09 | 再開されました | Jefferies | Buy |
| 2022-10-17 | 開始されました | JP Morgan | Neutral |
| 2022-08-29 | 開始されました | BofA Securities | Buy |
| 2021-12-13 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-05 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-08-26 | 開始されました | Morgan Stanley | Overweight |
| 2021-01-29 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-01-19 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-22 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-07-17 | 開始されました | Robert W. Baird | Outperform |
| 2020-07-01 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-28 | 開始されました | SunTrust | Buy |
| 2020-04-22 | 開始されました | Wedbush | Outperform |
| 2019-10-14 | 開始されました | Guggenheim | Buy |
| 2019-10-14 | 開始されました | Jefferies | Buy |
| 2019-10-14 | 開始されました | Piper Jaffray | Overweight |
| 2019-10-14 | 開始されました | Stifel | Buy |
すべてを表示
Igm Biosciences Inc (IGMS) 最新ニュース
State Street Corp Buys 12,174 Shares of IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
Trend Tracker for (IGMS) - Stock Traders Daily
IGM Biosciences stock hits 52-week low at $6.15 amid market challenges - Investing.com
Igm biosciences CEO sells $12,775 in stock By Investing.com - Investing.com Australia
Igm biosciences CEO sells $12,775 in stock - Investing.com India
Igm biosciences principal accounting officer sells shares for $4,031 - Investing.com India
Igm biosciences CFO sells shares worth $12,775 - Investing.com India
IGM Biosciences, Inc. (NASDAQ:IGMS) CEO Mary Beth Harler Sells 1,708 Shares - MarketBeat
Igm biosciences principal accounting officer sells shares for $4,031 By Investing.com - Investing.com UK
IGM Biosciences chief business officer sells shares worth $7,951 By Investing.com - Investing.com Canada
IGM Biosciences (NASDAQ:IGMS shareholders incur further losses as stock declines 21% this week, taking five-year losses to 84% - Simply Wall St
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Target Price at $17.75 - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $17.75 Average Target Price from Analysts - MarketBeat
IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism - Investing.com Australia
IGM Biosciences' SWOT analysis: stock pivot to autoimmune focus sparks analyst optimism By Investing.com - Investing.com South Africa
BMO Capital Markets Begins Coverage on IGM Biosciences (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Gap Up – Here’s What Happened - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Gap UpStill a Buy? - MarketBeat
BMO Capital Initiates Coverage of IGM Biosciences (IGMS) with Outperform Recommendation - MSN
IGM Biosciences (NASDAQ:IGMS) Coverage Initiated by Analysts at BMO Capital Markets - MarketBeat
BMO sets $21 target for IGM Biosciences with Outperform rating By Investing.com - Investing.com UK
IGM Biosciences: Dizzying Number Of Pivots (NASDAQ:IGMS) - Seeking Alpha
Quest Partners LLC Decreases Stock Position in IGM Biosciences, Inc. (NASDAQ:IGMS) - Defense World
IGM Biosciences (NASDAQ:IGMS) Shares Down 4.1%Should You Sell? - MarketBeat
How to Take Advantage of moves in (IGMS) - Stock Traders Daily
IGM Biosciences (NASDAQ:IGMS) Shares Gap DownHere's What Happened - MarketBeat
Brokerages Set IGM Biosciences, Inc. (NASDAQ:IGMS) Price Target at $16.13 - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Will Imvotamab Data Propel IGM Biosciences To New Heights In 2025? - RTTNews
How To Trade (IGMS) - Stock Traders Daily
FMR LLC Increases Stake in IGM Biosciences Inc - GuruFocus.com
IGM Biosciences Insiders Who Sold Avert US$165m Market Cap Dip - Simply Wall St
Biotech firm backs off its focus on oncology research - The Business Journals
IGM Biosciences (NASDAQ:IGMS) Given New $27.00 Price Target at Stifel Nicolaus - MarketBeat
Igm Biosciences: Navigating Financial Challenges Amidst Early-Stage Antibody Development - MSN
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
IGM Biosciences (NASDAQ:IGMS) Shares Down 7.8%Here's Why - MarketBeat
IGM Biosciences Inc (IGMS) Quarterly 10-Q Report - Quartz
IGM Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
IGM Biosciences earnings missed by $0.21, revenue topped estimates - Investing.com UK
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
IGM Biosciences Reports $61.4M Loss, Extends Cash Runway to 2027 Despite Clinical Progress | IGMS Stock News - StockTitan
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Igm Biosciences Inc (IGMS) 財務データ
収益
当期純利益
現金流量
EPS
1.76%
1.06%
大文字化:
|
ボリューム (24 時間):